dehydroepiandrosterone has been researched along with Anoxemia in 13 studies
Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Dehydroepiandrosterone reversed abnormal elevation of glutamate levels, shortenings of neuronal processes, decreases in the density of dendritic protrusions, downregulation of synaptosome-associated protein (SNAP25), and impaired cognition caused by hypoxia." | 8.12 | Dehydroepiandrosterone alleviates hypoxia-induced learning and memory dysfunction by maintaining synaptic homeostasis. ( Chen, R; Guan, R; Su, P; Wang, J; Yang, C; Zhang, J, 2022) |
| " To test our hypothesis that combining two drugs useful in experimental pulmonary hypertension, statins and dehydroepiandrosterone sulfate (DHEA S), is more effective than either agent alone, we induced pulmonary hypertension in adult male rats by exposing them to hypoxia (10%O2) for 3 weeks." | 8.12 | Simvastatin and dehydroepiandrosterone sulfate effects against hypoxic pulmonary hypertension are not additive. ( Chalupský, K; D Uris Ova, J; Hampl, V; Kaftanová, B; Krása, K; Miková, D; Minaříkova, M; Srbová, M; Vajnerova, O, 2022) |
| "Dehydroepiandrosterone (DHEA) prevents chronic hypoxia-induced pulmonary hypertension and associated right ventricle dysfunction in rats." | 7.78 | Dehydroepiandrosterone reverses chronic hypoxia/reoxygenation-induced right ventricular dysfunction in rats. ( Amor-Carro, Ó; Begueret, H; Bellance, N; Billaud, M; Dahan, D; dos Santos, P; Ducret, T; Dumas de La Roque, E; Fayon, M; Marthan, R; Ramos-Barbón, D; Rossignol, R; Savineau, JP, 2012) |
| "It has been reported that dehydroepiandrosterone is a pulmonary vasodilator and inhibits chronic hypoxia-induced pulmonary hypertension." | 7.74 | Dehydroepiandrosterone upregulates soluble guanylate cyclase and inhibits hypoxic pulmonary hypertension. ( Fagan, KA; Gebb, SA; Golembeski, SM; Homma, N; Imamura, M; Karoor, V; Limbird, J; McMurtry, IF; Nagaoka, T; Oka, M; Sakao, E, 2007) |
| "240 C57BL/6 mice were treated, from the age of 21 months until death, by normobaric hypoxia (11% FIO2) or normoxia, both with and without dehydroepiandrosterone sulfate (25 mg/kg in drinking water) (4 groups, N = 60)." | 7.73 | Hypoxia and dehydroepiandrosterone in old age: a mouse survival study. ( Baulieu, EE; Debonneuil, EH; Quillard, J, 2006) |
| "Dehydroepiandrosterone reversed abnormal elevation of glutamate levels, shortenings of neuronal processes, decreases in the density of dendritic protrusions, downregulation of synaptosome-associated protein (SNAP25), and impaired cognition caused by hypoxia." | 4.12 | Dehydroepiandrosterone alleviates hypoxia-induced learning and memory dysfunction by maintaining synaptic homeostasis. ( Chen, R; Guan, R; Su, P; Wang, J; Yang, C; Zhang, J, 2022) |
| " To test our hypothesis that combining two drugs useful in experimental pulmonary hypertension, statins and dehydroepiandrosterone sulfate (DHEA S), is more effective than either agent alone, we induced pulmonary hypertension in adult male rats by exposing them to hypoxia (10%O2) for 3 weeks." | 4.12 | Simvastatin and dehydroepiandrosterone sulfate effects against hypoxic pulmonary hypertension are not additive. ( Chalupský, K; D Uris Ova, J; Hampl, V; Kaftanová, B; Krása, K; Miková, D; Minaříkova, M; Srbová, M; Vajnerova, O, 2022) |
| " Dehydroepiandrosterone (DHEA) effectively treats experimental pulmonary hypertension in chronically hypoxic and monocrotaline-injected rats." | 3.79 | Dehydroepiandrosterone restores right ventricular structure and function in rats with severe pulmonary arterial hypertension. ( Abe, K; Alzoubi, A; Fagan, KA; McMurtry, IF; O'Neill, KD; Oka, M; Rocic, P; Toba, M, 2013) |
| "Dehydroepiandrosterone (DHEA) prevents chronic hypoxia-induced pulmonary hypertension and associated right ventricle dysfunction in rats." | 3.78 | Dehydroepiandrosterone reverses chronic hypoxia/reoxygenation-induced right ventricular dysfunction in rats. ( Amor-Carro, Ó; Begueret, H; Bellance, N; Billaud, M; Dahan, D; dos Santos, P; Ducret, T; Dumas de La Roque, E; Fayon, M; Marthan, R; Ramos-Barbón, D; Rossignol, R; Savineau, JP, 2012) |
| "It has been reported that dehydroepiandrosterone is a pulmonary vasodilator and inhibits chronic hypoxia-induced pulmonary hypertension." | 3.74 | Dehydroepiandrosterone upregulates soluble guanylate cyclase and inhibits hypoxic pulmonary hypertension. ( Fagan, KA; Gebb, SA; Golembeski, SM; Homma, N; Imamura, M; Karoor, V; Limbird, J; McMurtry, IF; Nagaoka, T; Oka, M; Sakao, E, 2007) |
| "240 C57BL/6 mice were treated, from the age of 21 months until death, by normobaric hypoxia (11% FIO2) or normoxia, both with and without dehydroepiandrosterone sulfate (25 mg/kg in drinking water) (4 groups, N = 60)." | 3.73 | Hypoxia and dehydroepiandrosterone in old age: a mouse survival study. ( Baulieu, EE; Debonneuil, EH; Quillard, J, 2006) |
| "Fetal hypoxemia was associated with dramatic increases in fetal plasma D, D sulfate, androstenedione, E1, and E2." | 1.28 | Fetal and maternal endocrine responses to reduced uteroplacental blood flow. ( Bethea, CL; Novy, MJ; Shepherd, RW; Stanczyk, FZ, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Guan, R | 1 |
| Yang, C | 1 |
| Zhang, J | 1 |
| Wang, J | 1 |
| Chen, R | 1 |
| Su, P | 1 |
| Krása, K | 3 |
| Vajnerova, O | 3 |
| D Uris Ova, J | 3 |
| Minaříkova, M | 3 |
| Miková, D | 3 |
| Srbová, M | 3 |
| Chalupský, K | 3 |
| Kaftanová, B | 3 |
| Hampl, V | 3 |
| Alzoubi, A | 1 |
| Toba, M | 1 |
| Abe, K | 1 |
| O'Neill, KD | 1 |
| Rocic, P | 1 |
| Fagan, KA | 2 |
| McMurtry, IF | 2 |
| Oka, M | 4 |
| Lefferts, WK | 1 |
| Babcock, MC | 1 |
| Tiss, MJ | 1 |
| Ives, SJ | 1 |
| White, CN | 1 |
| Brutsaert, TD | 1 |
| Heffernan, KS | 1 |
| Dumas de La Roque, E | 1 |
| Bellance, N | 1 |
| Rossignol, R | 1 |
| Begueret, H | 2 |
| Billaud, M | 1 |
| dos Santos, P | 2 |
| Ducret, T | 1 |
| Marthan, R | 2 |
| Dahan, D | 1 |
| Ramos-Barbón, D | 1 |
| Amor-Carro, Ó | 1 |
| Savineau, JP | 2 |
| Fayon, M | 2 |
| Bonnet, S | 1 |
| Dumas-de-La-Roque, E | 1 |
| Baulieu, EE | 3 |
| Debonneuil, EH | 1 |
| Quillard, J | 1 |
| Karoor, V | 1 |
| Homma, N | 1 |
| Nagaoka, T | 1 |
| Sakao, E | 1 |
| Golembeski, SM | 1 |
| Limbird, J | 1 |
| Imamura, M | 1 |
| Gebb, SA | 1 |
| Dessouroux, A | 1 |
| Akwa, Y | 1 |
| Gupte, SA | 2 |
| Li, KX | 1 |
| Okada, T | 2 |
| Sato, K | 1 |
| Tateyama, M | 1 |
| Ochi, R | 1 |
| Shepherd, RW | 1 |
| Stanczyk, FZ | 1 |
| Bethea, CL | 1 |
| Novy, MJ | 1 |
| Hakimowa, SH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-blind, Randomised, Placebo-controlled Phase III Study of Dehydroepiandrosterone (DHEA) in Respiratory Pulmonary Hypertension in Adults[NCT00581087] | Phase 3 | 60 participants (Anticipated) | Interventional | 2007-01-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for dehydroepiandrosterone and Anoxemia
| Article | Year |
|---|---|
Effect of hypoxia on cerebrovascular and cognitive function during moderate intensity exercise.
Topics: Bicycling; Cerebrovascular Circulation; Cognition; Cross-Over Studies; Dehydroepiandrosterone; Dehyd | 2016 |
12 other studies available for dehydroepiandrosterone and Anoxemia
| Article | Year |
|---|---|
Dehydroepiandrosterone alleviates hypoxia-induced learning and memory dysfunction by maintaining synaptic homeostasis.
Topics: Dehydroepiandrosterone; Glutamates; Hippocampus; Homeostasis; Humans; Hypoxia | 2022 |
Simvastatin and dehydroepiandrosterone sulfate effects against hypoxic pulmonary hypertension are not additive.
Topics: Animals; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Hypertension, Pulmonary; Hypoxia; M | 2022 |
Simvastatin and dehydroepiandrosterone sulfate effects against hypoxic pulmonary hypertension are not additive.
Topics: Animals; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Hypertension, Pulmonary; Hypoxia; M | 2022 |
Simvastatin and dehydroepiandrosterone sulfate effects against hypoxic pulmonary hypertension are not additive.
Topics: Animals; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Hypertension, Pulmonary; Hypoxia; M | 2022 |
Simvastatin and dehydroepiandrosterone sulfate effects against hypoxic pulmonary hypertension are not additive.
Topics: Animals; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Hypertension, Pulmonary; Hypoxia; M | 2022 |
Simvastatin and dehydroepiandrosterone sulfate effects against hypoxic pulmonary hypertension are not additive.
Topics: Animals; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Hypertension, Pulmonary; Hypoxia; M | 2022 |
Simvastatin and dehydroepiandrosterone sulfate effects against hypoxic pulmonary hypertension are not additive.
Topics: Animals; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Hypertension, Pulmonary; Hypoxia; M | 2022 |
Simvastatin and dehydroepiandrosterone sulfate effects against hypoxic pulmonary hypertension are not additive.
Topics: Animals; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Hypertension, Pulmonary; Hypoxia; M | 2022 |
Simvastatin and dehydroepiandrosterone sulfate effects against hypoxic pulmonary hypertension are not additive.
Topics: Animals; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Hypertension, Pulmonary; Hypoxia; M | 2022 |
Simvastatin and dehydroepiandrosterone sulfate effects against hypoxic pulmonary hypertension are not additive.
Topics: Animals; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Hypertension, Pulmonary; Hypoxia; M | 2022 |
Dehydroepiandrosterone restores right ventricular structure and function in rats with severe pulmonary arterial hypertension.
Topics: Animals; Apoptosis; Blood Pressure; Dehydroepiandrosterone; Fibrosis; Gene Expression; Heart Ventric | 2013 |
Dehydroepiandrosterone reverses chronic hypoxia/reoxygenation-induced right ventricular dysfunction in rats.
Topics: Animals; Apoptosis; CREB-Binding Protein; Dehydroepiandrosterone; Disease Models, Animal; Echocardio | 2012 |
Dehydroepiandrosterone (DHEA) prevents and reverses chronic hypoxic pulmonary hypertension.
Topics: Adjuvants, Immunologic; Administration, Oral; Animals; Blotting, Western; Calcium; Calcium Channels; | 2003 |
Hypoxia and dehydroepiandrosterone in old age: a mouse survival study.
Topics: Adjuvants, Immunologic; Aging; Animals; Dehydroepiandrosterone; Hypoxia; Longevity; Mice; Mice, Inbr | 2006 |
Dehydroepiandrosterone upregulates soluble guanylate cyclase and inhibits hypoxic pulmonary hypertension.
Topics: Acetylcholine; Animals; Blotting, Western; Cyclic GMP; Dehydroepiandrosterone; Dehydroepiandrosteron | 2007 |
DHEA decreases HIF-1alpha accumulation under hypoxia in human pulmonary artery cells: potential role in the treatment of pulmonary arterial hypertension.
Topics: Amino Acids, Dicarboxylic; Base Sequence; Cells, Cultured; Cobalt; Deferoxamine; Dehydroepiandroster | 2008 |
Inhibitors of pentose phosphate pathway cause vasodilation: involvement of voltage-gated potassium channels.
Topics: 6-Aminonicotinamide; Androsterone; Animals; Aorta, Thoracic; Dehydroepiandrosterone; Endothelium, Va | 2002 |
Epiandrosterone, a metabolite of testosterone precursor, blocks L-type calcium channels of ventricular myocytes and inhibits myocardial contractility.
Topics: Androsterone; Animals; Calcium; Calcium Channel Blockers; Calcium Channels, L-Type; Dehydroepiandros | 2002 |
Fetal and maternal endocrine responses to reduced uteroplacental blood flow.
Topics: Adrenocorticotropic Hormone; Androgens; Animals; Coronary Circulation; Dehydroepiandrosterone; Endoc | 1992 |
[On the question of locally conditioned peculiarities in the metabolism and excretion of steroid hormones in women under the climatic-geographic conditions of the Tadzhikistan Republic].
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Altitude; Androsterone; Chemistry, Clinical; Climate; De | 1968 |